Drug · CHEMBL501
AMPHETAMINE SULFATE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. AMPHETAMINE SULFATE. Drugs and targets, record CHEMBL501. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL501
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| SLC6A2 | Sodium-dependent noradrenaline transporter | Norepinephrine transporter releasing agent | RELEASING AGENT | https://conductscience.org/library/genes/6530 |
| SLC6A3 | Sodium-dependent dopamine transporter | Dopamine transporter releasing agent | RELEASING AGENT | https://conductscience.org/library/genes/6531 |
Source ChEMBL
Diseases5
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| attention deficit-hyperactivity disorder | Approval | DailyMed | 9 | 6 | https://conductscience.org/library/drugs?q=MONDO_0007743 |
| cocaine dependence | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005186 |
| stroke disorder | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005098 |
| narcolepsy-cataplexy syndrome | Approval | DailyMed | 3 | 0 | https://conductscience.org/library/drugs?q=MONDO_0016158 |
| obesity disorder | Approval | DailyMed | 1 | 0 | https://conductscience.org/library/drugs?q=MONDO_0011122 |
Source Open Targets
Trials7
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT03659929 | Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate | Phase 3 | 320 | 2024-09-03 | amphetamine sulfate | Its name | ClinicalTrials.gov |
| NCT01986062 | Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting | Phase 4 | 97 | 2016-04-19 | amphetamine sulfate | Its name | ClinicalTrials.gov |
| NCT03945175 | Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening | Phase 3 | 52 | 2023-06-29 | mydayis | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT00715520 | Neurobiological Principles Applied to the Rehabilitation of Stroke Patients | 33 | 2017-10-16 | amphetamine sulfate | Its name | ClinicalTrials.gov | |
| NCT00152035 | Safety of SPD465 in Treating Adults With ADHD. | Phase 3 | 505 | amphetamine sulfate | Its name | ClinicalTrials.gov | |
| NCT00150579 | Efficacy and Safety of SPD465 in Adults With ADHD | Phase 3 | 240 | amphetamine sulfate | Its name | ClinicalTrials.gov | |
| NCT00202605 | Safety and Efficacy of SPD465 in Adults With ADHD | Phase 2 | 72 | amphetamine sulfate | Its name | ClinicalTrials.gov |
Comparisons in its trials1
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| AR11 vs Placebo: serious adverse events | 0 of 97 | 0 of 97 | 194 | NCT01986062 |
Source Trial comparisons
Papers from its trials7
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL501
GET https://conductscience.org/api/drugs/v1/CHEMBL501/targets